Table 4.
Echocardiographic parameters.
| db/+CON | db/+DOX-5d | db/+DOX-7d | db/dbCON | db/dbDOX-5d | db/dbDOX-7d | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |
| HR (bpm) | 532 ± 15 | 503 ± 37 | 530 ± 24 | 463 ± 23* | 563 ± 6 | 497 ± 29* | 494 ± 28 | 503 ± 8 | 501 ± 20 | 476 ± 20 | 485 ± 21 | 411 ± 32* |
| AWT (cm) | 0.10 ± 0.01 | 0.10 ± 0.01 | 0.12 ± 0.01 | 0.10 ± 0.01* | 0.11 ± 0.01 | 0.09 ± 0.01* | 0.10 ± 0.01 | 0.13 ± 0.02 | 0.11 ± 0.01 | 0.11 ± 0.01 | 0.11 ± 0.01 | 0.09 ± 0.01* |
| PWT (cm) | 0.11 ± 0.01 | 0.10 ± 0.01 | 0.10 ± 0.01 | 0.08 ± 0.01* | 0.11 ± 0.01 | 0.09 ± 0.01* | 0.10 ± 0.01 | 0.12 ± 0.02 | 0.12 ± 0.01 | 0.12 ± 0.01 | 0.12 ± 0.01 | 0.10 ± 0.01* |
| LVEDD (cm) | 0.35 ± 0.01 | 0.35 ± 0.01 | 0.33 ± 0.01 | 0.34 ± 0.01 | 0.32 ± 0.01 | 0.36 ± 0.01 | 0.35 ± 0.02 | 0.33 ± 0.01 | 0.32 ± 0.01 | 0.33 ± 0.01 | 0.33 ± 0.01 | 0.26 ± 0.01* |
| LVESD (cm) | 0.07 ± 0.004 | 0.07 ± 0.01 | 0.06 ± 0.01 | 0.13 ± 0.01* | 0.06 ± 0.002 | 0.12 ± 0.01* | 0.12 ± 0.01** | 0.10 ± 0.006 | 0.10 ± 0.01 | 0.11 ± 0.004 | 0.11 ± 0.01 | 0.16 ± 0.01* |
| FS (%) | 81.5 ± 0.99 | 80.9 ± 2.11 | 80.9 ± 1.75 | 62.4 ± 1.96* | 82.5 ± 0.75 | 67.4 ± 1.11* | 65.7 ± 2.08** | 70.2 ± 0.92 | 69.3 ± 2.05 | 67.3 ± 1.08 | 67.7 ± 1.66 | 40.3 ± 4.99*** |
| EF (%) | 97.0 ± 0.32 | 96.7 ± 0.65 | 96.7 ± 0.61 | 87.8 ± 1.30* | 97.4 ± 0.22 | 90.1 ± 0.62* | 89.8 ± 1.21** | 91.2 ± 0.46 | 91.7 ± 1.12 | 90.8 ± 0.61 | 91.0 ± 0.91 | 69.5 ± 5.07*** |
Transthoracic echocardiography was conducted before (Pre) and after (Post) the 5 and 7-day experimental period to examine the ventricular parameters. db/+CON; non-diabetic control group; db/+DOX-5d, non-diabetic mice on day 5 with treatment of doxorubicin; db/+DOX-7d, non-diabetic mice on day 7 with treatment of doxorubicin; db/dbCON, diabetic control group; db/dbDOX-5d, diabetic mice on day 5 with treatment of doxorubicin; db/dbDOX-7d, diabetic mice on day 7 with treatment of doxorubicin. HR, heart rate; AWT, anterior wall thickness; PWT, posterior wall thickness; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; FS, fractional shortening; EF, ejection fraction.
P < 0.05 compared to the corresponding Pre (indicating the effects of DOX treatment on the heart);
P < 0.05 compared to db/+CON group at Pre (indicating the effects of diabetes on the heart);
P < 0.05 compared to the db/dbDOX-5d Post (indicating the time effects of doxorubicin treatment on diabetic heart).